Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NCT04913337 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

179

Enrollment

INDUSTRY

Sponsor class

Conditions

Mesothelioma
Glioblastoma
Renal Cell Carcinoma
Non Small Cell Lung Cancer
Melanoma
Pancreatic Ductal Adenocarcinoma
Gastric Cancer
Squamous Cell Carcinoma of Head and Neck
Cholangiocarcinoma
Breast Cancer
Ovarian Cancer
Cervical Cancer
Endocervical Cancer
Colorectal Cancer
Esophageal Cancer

Interventions

DRUG: NGM707
DRUG: NGM707 plus pembrolizumab (KEYTRUDA®)
DRUG: NGM707 plus pembrolizumab (KEYTRUDA®)
DRUG: NGM707 plus pembrolizumab (KEYTRUDA®)
DRUG: NGM707 plus pembrolizumab (KEYTRUDA®)
DRUG: NGM707
DRUG: NGM707
DRUG: NGM707

Sponsor

NGM Biopharmaceuticals, Inc

Collaborators

[object Object]